Last Updated on December 22, 2024 by The Health Master
USFDA Approval
USFDA Approval: In the fast-paced world of pharmaceuticals, Jubilant Pharmova Limited, through its subsidiary Jubilant Draximage Inc, has recently achieved a significant milestone.
The US Food and Drug Administration (USFDA) has given its nod to the company’s abbreviated new drug application (ANDA) for the preparation of Technetium (Tc 99m) Sulfur Colloid Injection, a crucial development in the field of nuclear medicine.
I. Introduction
This article delves into the details of this groundbreaking announcement, exploring the implications of USFDA approval and shedding light on the various aspects of Jubilant Pharmova Limited’s operations.
II. USFDA Approval and Exclusivity
The USFDA’s approval, granted under section 505(j) of the Federal Food, Drug, and Cosmetic Act, comes with the added benefit of 180 days of exclusivity.
This exclusivity, attributed to the ‘Competitive Generic Therapy’ designation, holds strategic importance in the competitive pharmaceutical landscape.
III. Technetium Sulfur Colloid Injection
Technetium Sulfur Colloid Injection plays a vital role in medical diagnostics.
Its applications range from localizing metastatic lymph nodes in breast cancer and melanoma patients to imaging areas of the liver, spleen, and bone marrow.
Additionally, it is instrumental in studies related to esophageal transit, gastroesophageal reflux, and the detection of pulmonary aspiration of gastric contents.
IV. Effective Date and Duration
The approval, effective from Nov 9, 2023, marks the beginning of a 180-day window where Jubilant Pharmova Limited can exclusively market this drug.
This period offers a competitive edge, allowing the company to establish its presence in the market.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA Approval granted for Fluphenazine Hydrochloride Tablets
USFDA Approval granted for this Revolutionary Weight Loss Drug
USFDA Approval granted for Sitagliptin and Metformin HCL Tablets
USFDA approval granted for Esomeprazole Magnesium Capsules: Granules
USFDA Approval: USFDA Approval granted for Apremilast Tablets
USFDA tentative approval granted for Apalutamide tablets
USFDA issues Form 483 with 10 observations to Dr Reddy’s Lab
Understanding the Draft National Pharmacy Commission Bill, 2023
MHRA approval granted for this Ophthalmology drug: Biocon
Bayer withdraws Follicular Lymphoma Drug from market: A Closer Look
CDSCO Extends Deadline for Digital Drugs Regulatory System
NPPA fixed Ceiling price of 9 scheduled formulations: November 2023
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
